Drug Trial Radar · NCT04673942
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Mar 29, 2021
Primary completion
Dec 1, 2026
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- EpicentRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Conditions
- Solid Tumor, Adult
- Cancer
- Neoplasms
- Sarcoma
- Sarcoma,Soft Tissue
- Chondrosarcoma
Interventions
AdAPT-001Biological
Oncolytic virus administered by intratumoral injection
Checkpoint Inhibitor, ImmuneDrug
Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: 28 days
- Maximum tolerated doseTime frame: 28 days
- Safety of a multiple dose regimen of AdAPT-001Time frame: 6 months
- Anti-tumor activity of the two-arm dose regimens of AdAPT-001 in Phase 2Time frame: 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
California Cancer Associates for Research and Excellence, cCARE
San Marcos, California
Providence Saint John's Health Center
Santa Monica, California
Cleveland Clinic
Cleveland, Ohio
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.